Clinical Trial to Evaluate the Long-term Safety of Udenafil in Patient With PAH

Summary

This study evaluates the long-term safety of Udenafil in Patient with Pulmonary Arterial Hypertension(PAH). All the patients will receive Udenafil for 1-year(48-weeks).

Timeline

Start

2014-04

Primary completion

2016-02

Completion

2016-02

Drugs

Indications